This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Immunogen's 'Smart Bomb' Cancer Drugs Are Flunking Safety Checks

Stocks in this article: IMGN RHHBY SGEN

The list of toxicity problems linked to Immunogen's  (IMGN) "smart bomb" cancer drugs is growing longer. Investors should be entertaining the possibility Immunogen's entire antibody-drug conjugates (ADC) technology platform might need to be scrapped or at least completely overhauled.

Immunogen shares are down 15% to $14.01 Tuesday after an unacceptable number of infections, some of which cause patients to die, forced the company to shut down a study of IMGN901 in small cell lung cancer patients, Immunogen announced. Independent data monitors also concluded IMGN901 had no chance of benefiting patients in the study.

IMGN901 is ImmunoGen's lead drug candidate so Tuesday's news is particularly troublesome. 

In October, Immunogen said some cancer patients treated with SAR566658, an early-stage drug licensed to Sanofi, reported eye toxicity when higher doses of the drug were used. 

In August, Immunogen acknowledged that toxicities attributed to two other wholly-owned cancer drugs -- IMGN853 and IMGN529 -- was forcing the company to use lower-than-expected doses in future, planned studies.

All of Immunogen's ADC cancer drugs link a monoclonal antibody, which targets a specific protein found on cancer cells, with a toxic payload of chemotherapy. The goal is to deliver the toxic payload inside cancer cells where it can do the most damage but prevent the chemotherapy from harming healthy cells. Seattle Genetics  (SGEN) used its own ADC technology to develop the lymphoma drug Adcetris. 

The chemical linker which attaches the toxic chemotherapy payload to the monoclonal antibody is the most crucial part of any ADC drug. If the linker is too tight, the chemotherapy won't release in sufficient quantities inside the tumor to do its job. If the linker is too loose, the chemotherapy might release outside the tumor cell, causing too unacceptable toxicity. 

ImmunoGen hasn't provided much detail about the safety problems with its ADC drug candidates, but the list of toxicities suggest its linker(s) are too loose. 

Up until now, a lot of investors have disregarded the risks associated with Immunogen's technology platform because of the approval and early commercial success of the breast cancer drug Kadcyla, which was developed by Roche using its own monoclonal antibody (Herceptin) combined with a linker and chemotherapy payload from Immunogen.

What most investors don't realize, however, is that Roche radically re-engineered the Immunogen linker and chemotherapy to make Kadcyla work. This was proprietary work done by Roche that hasn't extended to Immunogen's other ADC drug candidates.

Which is why Kadycla was approved and the rest of Immunogen's pipeline is blowing up, or at risk of blowing up, due to safety problems.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter. X

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs